Optimer Binder Adjuvants for Swine Vaccines

Technology
In development
University
Scouted & summarized by Halo AI

The University of Glasgow has secured exclusive rights to a panel of synthetic Optimer binders to be developed as novel, high-performance vaccine adjuvants for the swine health market. These synthetic molecules offer a stable and effective alternative to traditional antibodies, with preclinical evidence demonstrating strong immune-enhancing capabilities. The initiative aims to commercialize these advanced adjuvants within the next 12 months to address the global demand for improved veterinary vaccine efficacy.

Overview

Optimer binders are advanced, synthetic molecules engineered to function like antibodies by binding to specific targets. Through a licensing agreement, the University of Glasgow is leveraging a specialized panel of these binders as novel, highly effective vaccine adjuvants to enhance swine health. These synthetic alternatives are designed to improve immune responses, offering a scalable and versatile solution to meet the growing demand for advanced veterinary vaccines.

Technical specifications
  • Synthetic design: Engineered for high stability and reliable performance compared to traditional biological antibodies.
  • Functionality: Act as immune-enhancing adjuvants, specifically optimized to improve the efficacy of swine vaccines.
  • Proven performance: Demonstrated strong, positive immune-enhancing capabilities during preclinical trials led by the University of Glasgow.
  • Commercial versatility: Designed to be easily integrated into vaccine development workflows, addressing a global market with a need for enhanced disease protection and farming efficiency.
Technology readiness level

The technology is currently at TRL 5. Having completed successful preclinical studies that demonstrated the binders' functional capabilities, the program is now in the product development phase, with commercialization anticipated within the next 12 months.

Generated Jul 7, 2026. Please verify key information.

About University of Glasgow

The University of Glasgow is a comprehensive, research‑intensive public university in Scotland’s largest city. Industry collaborates via the James Watt Nanofabrication Centre—an advanced university cleanroom—and hospital‑based facilities at the Queen Elizabeth University Hospital, including the Imaging Centre of Excellence with NHS Greater Glasgow & Clyde. The adjacent West of Scotland Science Park offers grow‑on space for companies and strong links back to campus. Research is supported by competitive funding from UK Research and Innovation councils and major charities such as Wellcome. Research & Innovation Services manages IP, licensing and spin‑out formation to speed commercialization.

Halo home
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.